Condition 1: acne,. Condition 2: skin dehydration,. Condition 3: sun-induced hyperpigmentation or melanocyte alterations. Condition 4: reduced skin elasticity. Condition 5: skin laxity. Condition 6: decreased collagen content. Condition 7: Cutaneous aging. Acne Other melanin hyperpigmentation
Conditions
Interventions
Intervention 1: Intervention group: the intervention group includes patients who have used film. In the intervention group, each patient is evaluated before (the control group) and after (the first in
Sponsors
Nano Oxin Daroo Company
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: All patients with common skin disorders such as acne All patients with common skin disorders such as skin dehydration All patients with common skin disorders such as sun-induced hyperpigmentation or melanocyte alterations All patients with common skin disorders such as reduced skin elasticity All patients with common skin disorders such as skin laxity and decreased collagen content
Exclusion criteria
Exclusion criteria: All patients with autoimmune disorders All patients with skin cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin sensitivity. Timepoint: At the beginning of phase II of the study (before initiation of the intervention) and on days 3, 7, and 14 after the start of film application. Method of measurement: Clinical evaluation of the skin by a board-certified dermatologist through direct examination and documentation of cutaneous hypersensitivity signs, including erythema, swelling, pruritus, and inflammation at the film application site.;The speed of effectiveness in film. Timepoint: The speed of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month) and week 12 (third month) after initiation of film use. Method of measurement: Assessment of the speed of the film’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| The level of effectiveness in film to decrease or stop the skin disorder. Timepoint: The level of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month) and week 12 (third month) after initiation of film use. Method of measurement: Assessment of the level of the film’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist.;The potency of film to decrease or stop the skin disorder. Timepoint: The potency of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month) and week 12 (third month) after initiation of film use. Method of measurement: Assessment of the potency of the film’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Izadyari Aghmiuni
Nano Oxin Daroo Company
Outcome results
None listed